15 hours ago 1

Galapagos NV (GLPG)’ CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial

Thu, Sep 11, 2025, 10:18 AM 2 min read

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Galapagos NV is one of them.

Galapagos NV (NASDAQ:GLPG) is a Belgian-based firm and is carving out a leading position in next-generation oncology through its CAR-T programs and decentralized manufacturing model, designed to deliver faster, more accessible treatments for patients with hematological cancers. It is among the best performing stocks.

Galapagos NV (NASDAQ:GLPG)’s momentum centers on GLPG5101, a CAR-T therapy for B-cell lymphomas. Recently, the FDA granted it an RMAT designation for relapsed/refractory mantle cell lymphoma, recognizing the promise shown in the ongoing Phase 1/2 ATALANTA-1 trial. The company also reported striking data at the 2025 ICML conference, with a 97% complete response rate and 100% MRD negativity in patients with indolent non-Hodgkin lymphoma. With a vein-to-vein time of just seven days, the therapy stands out from traditional CAR-T products.

Building on this success, the business is expanding ATALANTA-1 to new cohorts, including Richter transformation and chronic lymphocytic leukemia. Meanwhile, its second CAR-T candidate, GLPG5301, targeting multiple myeloma, is advancing through early development. These efforts highlight the corporation’s push to broaden its pipeline across high-need cancer indications.

Galapagos NV (GLPG)’ CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial

A major differentiator for Galapagos NV (NASDAQ:GLPG) is its decentralized manufacturing platform, which allows “fresh” CAR-T therapies to be produced closer to patients. Recent collaborations with the Moffitt Cancer Center in the U.S. and CELLforCURE in Paris are strengthening this model, ensuring scalability and faster access.

While we acknowledge the potential of GLPG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.